Preclinical studies and clinical trials have sparked interest in certain gene therapy strategies for atherosclerotic Coronary Heart Disease.
Moataz Dowaidar
Abstract
In recent years, an amazing array of innovative therapeutic approaches has been built in our battle against atherosclerotic Coronary Heart Disease. These cutting-edge therapeutic methods range from vaccines to protein, mRNA, genome, and even DNA base modulation to treat atherosclerotic Coronary Heart Disease. Although the molecular targets studied by these approaches are largely the same, some of them are safer and more targeted against specific targets due to technical advantages and limitations. Preclinical studies and clinical trials have sparked interest in certain biological medications for the treatment of atherosclerotic Coronary Heart Disease, although others have stalled. With bated breath, we await the results of the clinical trial. Both of these treatment choices, however, have major disadvantages. As a result of their acquired experience and ongoing efforts to overcome them, their transition to the clinical community could be improved in the coming years.